Allakos Stock Today
| ALLK Stock | USD 0.25 0.01 3.85% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Allakos is selling for 0.25 as of the 15th of March 2025. This is a 3.85 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.24. Allakos has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 15th of December 2024 and ending today, the 15th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of July 2018 | Category Healthcare | Classification Health Care |
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California. The company has 89.34 M outstanding shares of which 2.39 M shares are presently shorted by private and institutional investors with about 0.72 trading days to cover. More on Allakos
Moving together with Allakos Stock
Moving against Allakos Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Allakos Stock Highlights
| CEO, Director | Robert Alexander | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsAllakos can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Allakos' financial leverage. It provides some insight into what part of Allakos' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Allakos (ALLK) is traded on NASDAQ Exchange in USA. It is located in 825 Industrial Road, San Carlos, CA, United States, 94070 and employs 9 people. Allakos is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.07 M. Allakos conducts business under Biotechnology sector and is part of Health Care industry. The entity has 89.34 M outstanding shares of which 2.39 M shares are presently shorted by private and institutional investors with about 0.72 trading days to cover.
Allakos currently holds about 212.44 M in cash with (93.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Allakos Probability Of Bankruptcy
Ownership AllocationAllakos holds a total of 89.34 Million outstanding shares. The majority of Allakos outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Allakos to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Allakos. Please pay attention to any change in the institutional holdings of Allakos as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Allakos Ownership Details
Allakos Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2024-12-31 | 1.4 M | |
| Ra Capital Management, Llc | 2024-12-31 | 1.1 M | |
| Rock Springs Capital Management Lp | 2024-12-31 | 1.1 M | |
| Ikarian Capital, Llc | 2024-12-31 | 972 K | |
| Geode Capital Management, Llc | 2024-12-31 | 962.1 K | |
| Ubs O'connor Llc | 2024-12-31 | 936.8 K | |
| Renaissance Technologies Corp | 2024-12-31 | 844.2 K | |
| Junked Platinum Investment Management Ltd | 2024-12-31 | 816 K | |
| Barclays Plc | 2024-12-31 | 755 K | |
| Bvf Inc | 2024-12-31 | 16.6 M | |
| Nea Management Company, Llc | 2024-12-31 | 6.1 M |
Allakos Historical Income Statement
Allakos Stock Against Markets
Allakos Corporate Management
| Alan Chang | Director Analytics | Profile | |
| Brad Youngblood | Head Research | Profile | |
| Craig MD | Chief Officer | Profile | |
| Henrik Rasmussen | Chief Medical Officer | Profile | |
| Baird III | Chief Officer | Profile | |
| Mary Cromwell | Chief Officer | Profile |
Already Invested in Allakos?
The danger of trading Allakos is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Allakos is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Allakos. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Allakos is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Allakos is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Allakos Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Allakos Stock. Highlighted below are key reports to facilitate an investment decision about Allakos Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allakos. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Allakos Stock please use our How to buy in Allakos Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allakos. If investors know Allakos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allakos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allakos is measured differently than its book value, which is the value of Allakos that is recorded on the company's balance sheet. Investors also form their own opinion of Allakos' value that differs from its market value or its book value, called intrinsic value, which is Allakos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allakos' market value can be influenced by many factors that don't directly affect Allakos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allakos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allakos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allakos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.